Metagenomi TherapeuticsMGX +4.13%10 EV-to-FCF is 0.61 as of Jul. 03, 2026, which is 32% below its 10-year median of 0.90. GuruFocus rates MGX with a GF Score™ of 10/100. The stock has 4 warning signs investors should review. Among 332 Biotechnology companies, Metagenomi Therapeutics ranks better than 83.13% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Metagenomi Therapeutics's Enterprise Value is $-53.54 Mil.
Metagenomi Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-87.54 Mil. Therefore, Metagenomi Therapeutics's EV-to-FCF for today is 0.61.
The historical rank and industry rank for Metagenomi Therapeutics's EV-to-FCF or its related term are showing as below:
MGX'
s EV-to-FCF Range Over the Past 10 Years
Min: -2.32 Med: 0.9 Max: 1.88
Current: 0.61
During the past 5 years, the highest EV-to-FCF of Metagenomi Therapeutics was 1.88. The lowest was -2.32. And the median was 0.90.
MGX's EV-to-FCF is ranked better than 83.13% of 332
companies
in the Biotechnology industry
Industry Median: 16.26
vs MGX: 0.61
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Metagenomi Therapeutics's PE Ratio (TTM) for today is calculated as:
Metagenomi Therapeutics's share price for today is $1.26.
Metagenomi Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.300.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Metagenomi Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metagenomi Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Metagenomi Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Metagenomi Therapeutics's EV-to-FCF falls into.
Metagenomi Therapeutics's current Enterprise Value is $-53.54 Mil.
Metagenomi Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-87.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metagenomi Therapeutics (MGX) has a EV-to-FCF of 0.61 as of Jul. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Metagenomi Therapeutics and its competitors. This is 32% below median its historical median of 0.90. According to the industry distribution chart, Metagenomi Therapeutics ranks #56 out of 332 companies in the Biotechnology industry, placing it in the top 16.9%.
Is Metagenomi Therapeutics' EV-to-FCF too high?
Metagenomi Therapeutics' current EV-to-FCF of 0.61 is 32% below median its 10-year median of 0.90. The Biotechnology industry median EV-to-FCF is 16.26. Metagenomi Therapeutics' value of 0.61 is 96.2% below this industry median. Based on the distribution chart, Metagenomi Therapeutics ranks #56 out of 332 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Metagenomi Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Metagenomi Therapeutics' EV-to-FCF compare to KALA and HYPD?
According to the Biotechnology industry distribution chart, Metagenomi Therapeutics ranks #56 out of 332 companies for EV-to-FCF. This places Metagenomi Therapeutics in the top 17% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 16.26. Metagenomi Therapeutics' value of 0.61 is 96.2% below this benchmark. While the company's 10-year median is 0.90 vs. the industry median of 16.26, Metagenomi Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.26, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Metagenomi Therapeutics's current EV-to-FCF of 0.61 is 96.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Metagenomi Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metagenomi Therapeutics's current EV-to-FCF is 0.61, which is 32% below median its own 10-year median of 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metagenomi Therapeutics stock overvalued right now?
Metagenomi Therapeutics (MGX) has a current EV-to-FCF of 0.61. The current EV-to-FCF is 0.61, which is 32% below median its 10-year median of 0.90 and 96.2% below the Biotechnology industry median of 16.26. Metagenomi Therapeutics' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Metagenomi Therapeutics (MGX), the current EV-to-FCF is 0.61 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
10GF Score
Get the complete analysis for MGX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MGX has been successfully added to your 
